July trial date set for UCD researcher accused of visa fraud davisenterprise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from davisenterprise.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad .
Myriad Genetics, Inc.February 12, 2021 GMT
SALT LAKE CITY, Feb. 12, 2021 (GLOBE NEWSWIRE) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today additional data further validating the prognostic power of its Prolaris® test and its ability to help accurately predict which men with more aggressive prostate cancer will benefit from intensification of therapy and which patients may safely avoid such treatments. This second validation study was presented during an oral presentation at the American Society of Clinical Oncology Genitourinary Cancer Symposium (ASCO-GU) by Jonathan Tward M.D., Ph.D, associate professor in the Department of Radiation Oncology at the University of Utah.
Maurice Iwu
Scientists have advanced more cures for COVID-19. Top on the list are: combination of ivermeticin, zinc and vitamin C; Andrographis paniculata, the key ingredient of IHP Detox Tea; extract of Artemisia annua, which interferes with replication of SARS-CoV-2; snake venom enzyme; metformin; colchicine, melatonin; and essential oils.
Reacting to the advances in traditional medicine as cures for COVID-19, the pioneer of natural cures for COVID-19 in Nigeria, Chief Executive Officer (CEO) of Bioresources Development and Conservation Programme (BDCP) and a professor of pharmacognosy, Maurice Iwu, told The Guardian: “The containment of the pandemic has not failed. It is rather a work in progress. We understand the virus better now. I believe that soon Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS CoV-2) will be like any other persistent virus and not so deadly.”
Share this article
Share this article
SUNNYVALE, Calif., Jan. 19, 2021 /PRNewswire/ Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective, phase II trial of 338 women with low-risk breast cancer showed 98.8 percent had local disease control seven years after receiving once-daily accelerated partial breast irradiation (APBI) delivered with the TomoTherapy
® System. The study, published online in the
International Journal of Radiation Oncology Biology Physics, also reported that the once-daily schedule was associated with a very low incidence of acute and late toxicities.
The TomoTherapy platform, including the next-generation Radixact
® System, is the first in the world capable of helical radiation delivery. Image-guided, intensity-modulated radiation therapy (IG-IMRT) is continuously delivering from a full 360 degrees around the patient as the treatment table also moves at a deliberate pace, providing greater control of the radiation dose so it
Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases
Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging
Getty Images
January 18, 2021 Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced that the first patient has been dosed in its Phase 3 REVELATE clinical trial of 18F-fluciclovine, a positron emission tomography (PET) imaging radiopharmaceutical being studied for potential use in detecting recurrent brain metastases. The REVELATE study is a Phase 3, multi-center, single-arm imaging study being conducted in the United States. Its purpose is to assess the diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases in patients previously treated with radiation therapy. The firs